TABLE 2

Annualized rates of progression to abnormal glucose tolerance

NGTProgression to FPG ≥6.1 mmol/l
Progression to 2hPG ≥7.8 mmol/l
Outcomes (n)Person-yearsRate/10095% CIOutcomes (n)Person-yearsRate/10095% CI
Overall885,1511.711.38–2.092604,0396.445.69–7.25
 5-year cumulative incidence7.431.1
 10-year cumulative incidence13.547.5
Age
 ≥65 years201,0012.001.25–3.018469612.19.67–14.83
 <65 years684,1511.641.28–2.061763,3435.274.53–6.08
P0.4<0.0001
1st degree relative with diabetes
 Yes281,3782.031.37–2.88731,0496.965.48–8.68
 No603,7731.591.22–2.031872,9906.255.40–7.19
P0.30.4
Sex
 Female202,0850.960.60–1.44821,7054.813.84–5.93
 Male683,0662.221.73–2.791782,3347.636.56–8.80
P0.00040.0004
Overall obesity
 BMI ≥25 kg/m2471,7742.651.96–3.481181,2499.457.85–11.26
 BMI <25 kg/m2413,3771.210.88–1.621422,7905.094.30–5.97
P0.0003<0.0001
Central obesity
 Waist ≥88 (women) or 102 cm (men)82403.341.53–6.212116812.57.88–18.61
 Waist <88 (women) or 102 cm (men)784,8641.601.27–1.992353,8296.145.39–6.96
P0.070.01
IFG-IGTProgression to FPG ≥7.0 mmol/l
Progression to 2hPG ≥11.1 mmol/l
IFG-IGT after NGT at baseline101,5520.640.32–1.13411,4802.772.01–3.71
 5-year cumulative incidence1.25.7
 10-year cumulative incidence8.828.4
IFG-IGT at baseline262,6470.980.65–1.411012,1924.613.77–5.56
 5-year cumulative incidence2.821.0
 10-year cumulative incidence8.337.4